By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Metabolon said today it is using its metabolomic technology to discover therapeutic targets and biomarkers under a collaboration with Takeda Pharmaceutical.

Under the multi-year deal, Metabolon will apply its analytical platform and software to discover and validate targets and to identify novel pharmacodynamic biomarkers for translation into the clinic.

Financial and other terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.